Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disease. MSA causes problems with control of movement, balance and autonomic functions like blood pressure and body temperature control. It impacts areas in the brain responsible for movement, balance and automatic body functions. Symptoms include stiff muscles, involuntary jerky movements, poor balance and coordination and problems with speech and swallowing. Due to autonomic features, MSA patients also experience problems in bladder control, bowel control, blood pressure regulation and sweating. The need for therapeutics to address these challenging symptoms associated with MSA has driven research and development of new treatment options.
The Multiple System Atrophy (MSA) Market is estimated to be valued at US$ 137.3 Mn in 2024 and is expected to exhibit a CAGR of 4.4% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the Multiple System Atrophy (MSA) are Chelsea Therapeutics International, Ltd., Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, Theravance Biopharma, Inc. and Among Others. These players are engaged in developing novel therapeutics to address unmet needs in MSA treatment.
The market presents high growth opportunities in research and development of disease modifying drugs for MSA. Development of drugs targeting underlying causes can potentially alter disease progression. Several candidates are in preclinical and clinical trials targeting pathophysiological mechanisms of MSA.
The market is also witnessing increased focus on expansion into emerging Asian and Latin American markets. Key players are partnering with regional biotech companies and exploring distributor networks to drive global accessibility of MSA treatment options.
Market drivers: Increasing incidence and prevalence of neurodegenerative disorders like Parkinson's disease and MSA worldwide is a key growth driver. Rising geriatric population who are more prone to such conditions further propels the market. Improving diagnostic capabilities is also facilitating early detection and management of MSA cases.
Market restrain: Limited understanding of underlying disease pathogenesis poses challenges to development of disease modifying treatments for MSA. Difficulties in differentiating MSA from other Parkinsonian disorders can hamper accurate diagnosis and clinical trials. Strict regulatory pathways for neurodegenerative disease therapies act as a barrier.
Segment Analysis
The Multiple System Atrophy (MSA) market is segmented into nigrostriatal (MSA-P, Parkinsonism symptoms) and olivopontocerebellar (MSA-C; cerebellar ataxia and dysautonomia) sub segments. The nigrostriatal sub segment dominates the market as MSA-P disease variant constitutes about two-thirds of all MSA cases. Patients with MSA-P usually present with Parkinson-like symptoms such as rigidity, bradykinesia, and postural instability more prominently than other non motor features like autonomic failure or cerebellar ataxia.
Global Analysis
North America region is the fastest growing and dominating region in the MSA market owing to presence of major pharmaceutical companies, high healthcare expenditure and increasing research and development activities in the region. Asia Pacific region is also expected to show significant growth during the forecast period backed by rising awareness, improving healthcare infrastructure and growing disposal incomes in emerging economies like India and China.
Get more insights on this topic: https://www.marketwebjournal.com/multiple-system-atrophy-msa-market-is-in-trends-due-to-growing-prevalence-of-neurodegenerative-diseases/
Author Bio
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups. (LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
What Are The Key Data Covered In This Multiple System Atrophy (MSA) Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Multiple System Atrophy (MSA) 's growth between 2024 and 2031.
:- Accurate calculation of the size of the Multiple System Atrophy (MSA) and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Multiple System Atrophy (MSA) Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Multiple System Atrophy (MSA) vendors
FAQ’s
Q.1 What are the main factors influencing the Multiple System Atrophy (MSA) ?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Multiple System Atrophy (MSA) companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Multiple System Atrophy (MSA) ’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it